Abbott Laboratories (VIE:ABT)
Austria · Delayed Price · Currency is EUR | Market Cap | 143.84B -30.4% |
| Revenue (ttm) | 39.14B +6.6% |
| Net Income | 5.42B -53.5% |
| EPS | 3.10 -53.6% |
| Shares Out | n/a |
| PE Ratio | 26.53 |
| Forward PE | 16.78 |
| Dividend | 2.09 (2.52%) |
| Ex-Dividend Date | Apr 15, 2026 |
| Volume | 456 |
| Open | 78.06 |
| Previous Close | 78.50 |
| Day's Range | 78.06 - 86.84 |
| 52-Week Range | 70.10 - 116.14 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 16, 2026 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, h... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.50 billion, a decrease of -51.49%.
Financial numbers in USD Financial StatementsNews
Abbott Laboratories Earnings Call Transcript: Q2 2026
Second quarter sales grew 4.8% with adjusted EPS of $1.31, exceeding expectations. Full-year sales growth guidance was reaffirmed and EPS guidance raised, with strong momentum in nutrition, diagnostics, and medical devices. Key product launches and pipeline investments support future growth.
Abbott Laboratories Earnings release: Q2 2026
Abbott Laboratories released its Q2 2026 earnings on July 16, 2026, summarizing the period's financial results.
Abbott Laboratories Slides: Q2 2026
Abbott Laboratories has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 16, 2026.
Abbott Laboratories Sales Rise on Diagnostics Growth
The healthcare company said its profit fell to $928 million, or 53 cents a share, in the second quarter, from $1.78 billion, or $1.01 a share, a year earlier.
Abbott raises 2026 profit forecast on heart device strength
Abbott raised its annual profit forecast on Thursday, as it expects strong demand for its heart devices in the second half of the year.
Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
Second-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percent Second-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.31 Abbott reaffirms full-year 2026 com...
Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.
This relationship between inflation and value stocks' outperformance is often overlooked. Many investment experts mistakenly believe that a strong economy, not inflation, is the key to value stocks be...
US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports
The U.S. Justice Department closed a criminal probe into Abbott Laboratories over how it managed a baby formula facility where potentially deadly bacteria were discovered and suspected of cau...
The Baby Formula Probe Produced a Pile of Evidence. Then the DOJ Dropped the Case.
WASHINGTON—The Justice Department spent years investigating Abbott Laboratories ABT 0.94%increase; up pointing triangle over how it managed a baby formula facility where potentially deadly bacteria wa...
Abbott hosts conference call for second-quarter earnings
ABBOTT PARK, Ill., June 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2026 financial results on Thursday, July 16, before the market opens.
ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing
ALZpath Strengthens Market Leadership with Abbott Agreement to Help Enable Early Alzheimer's Diagnosis at Global Scale CARLSBAD, Calif., June 24, 2026 /PRNewswire/ -- ALZpath Inc., the leader in bloo...
ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test
ALZpath said on Wednesday it had signed a global licensing agreement with Abbott Laboratories to help advance blood-based testing for Alzheimer's disease, as companies race to offer easier-to-use di...
Missouri appeals court won't send Abbott's appeal of $495 million preterm baby formula verdict to higher court
A Missouri appeals court on Monday declined to send Abbott Laboratories' appeal of a $495 million verdict in a case claiming the company's specialized formula for premature infants caused an Illinoi...
New Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents
Despite optimism about parenthood, unrealistic online portrayals are adding pressure for today's young parents Through the new "Love Without Measure" initiative, Similac is standing with parents in pr...
Abbott declares 410th consecutive quarterly dividend
ABBOTT PARK, Ill., June 12, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.
New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
Study at ADA's Scientific Sessions shows participants in Abbott's Healthy Food Rx program combined with health coaching had significant health improvements Abbott's Healthy Food Rx program is a Food i...
New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect early Ketone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and de...
Abbott Labs must face lawsuit over PediaSure children's growth claims
Abbott Laboratories must defend against a proposed class-action lawsuit claiming it misled consumers into believing its PediaSure Grow & Gain nutrition drinks were "clinically proven" to help childre...
Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabe...
ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
Cologuard® and Cologuard Plus® reaffirmed as preferred options for noninvasive colorectal cancer (CRC) screening in updated American Cancer Society guideline Abbott to offer only CRC screening portfol...
Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remission New MRD data from the PARTNER study demons...
